Skip to main content
    B

    Beta Bionics, Inc. Common Stock (BBNX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $15.21
    -1.21 (-7.37%)

    Market Cap: $892.71M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Beta Bionics, Inc. Common Stock (BBNX) Earnings: Report Dates and Results

    Updated Oct 27, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Beta Bionics, Inc. Common Stock (BBNX) is expected to report earnings on Feb 15, 2027. In the quarter ended Sep 30, 2026, Beta Bionics, Inc. Common Stock reported EPS of -$0.52, above the -$0.53 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    75%(6/8)
    Avg Surprise
    -10.80%
    Streak
    6 Q

    Upcoming Estimates

    Reports Feb 15, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.51
    Range-$0.62 - -$0.45
    16 analysts
    Revenue Consensus
    $31.03M
    Range$28.21M - $33.91M
    16 analysts
    Reports Apr 19, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.53
    Range-$0.62 - -$0.43
    2 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.57+7.1%
    60d ago-$0.56+5.4%
    30d ago-$0.53+0.9%
    7d ago-$0.53+0.9%
    Current-$0.53
    Revenue Consensus
    $35.34M
    Range$33.20M - $38.10M
    10 analysts

    Next Report

    BBNX has an expected report date of Feb 15, 2027.

    BBNX Earnings Call

    The latest BBNX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 8 quarters below that had an estimate, BBNX beat 6 and missed 2. Revenue for the quarter ended Sep 30, 2026 was $35.51M, up 30.3% from $27.25M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.52-$0.53-$0.55 - -$0.46+1.89%BeatN/A31 up, 0 downOct 27, 2026$35.51M
    Jun 30, 2026-$0.53-$0.62-$0.66 - -$0.46+14.52%BeatN/A20 up, 1 downJul 29, 2026$32.01M
    Mar 31, 2026-$0.36-$0.45-$0.52 - -$0.36+20.00%BeatN/A52 up, 2 downApr 21, 2026$27.63M
    Dec 31, 2025-$0.30-$0.38-$0.48 - -$0.28+21.05%BeatN/A91 up, 0 downFeb 17, 2026$32.12M
    Sep 30, 2025-$0.33-$0.41N/A+19.51%BeatN/AN/AN/AOct 28, 2025$27.25M
    Jun 30, 2025-$0.27-$0.47N/A+42.55%BeatN/AN/AN/AJul 29, 2025$23.24M
    Mar 31, 2025-$0.93-$0.51N/A-82.35%MissN/AN/AN/AMay 6, 2025$17.64M
    Dec 31, 2024-$2.72-$1.22N/A-123.56%MissN/AN/AN/AJan 31, 2025$20.44M
    Sep 30, 2024-$0.82N/AN/AN/AN/AN/AN/AN/ANov 27, 2024$16.70M
    Last 9 quarters

    Annual EPS

    Fiscal year endedEPSChange
    Sep 30, 2026-$1.41N/A
    Jun 30, 2026-$0.89N/A
    Dec 31, 2025-$1.83N/A
    Jun 30, 2025-$1.05N/A
    Dec 31, 2024-$3.54N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,100 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,06916
    2026Q2Jun 30, 20265,81615
    2026Q1Mar 31, 20267,57315
    2025Q4Dec 31, 20259,53817
    2025Q3Sep 30, 20258,08914
    2025Q2Jun 30, 20258,77412
    2025Q1Mar 31, 20259,06411

    2026Q3 Earnings Call

    Opening remarks

    Blake Beber Head of Investor Relations Good afternoon, and thank you for joining Beta Bionics' third quarter 2026 earnings call. With me on today's call are Chief Executive Officer Sean Saint and Chief Financial Officer Stephen Feider. Both the replay of this call and the press release discussing our third quarter 2026 results will be available on the Investor Relations section of our website. Information recorded on this call speaks only as of today, October 27, 2026. If you are listening to a replay of this call, any time-sensitive information may no longer be accurate. Also on our website are our supplemental third quarter 2026 earnings presentation and updated corporate presentation. We encourage you to refer to those documents for a summary of key metrics and business updates. Before we begin, we'd like to remind you that today's discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect management's expectations about future events, our product pipeline, development timelines, financial performance, and operating plans, and speak only as of today's date. Please refer to the cautionary statements in the press release we issued earlier today for a detailed explanation of the inherent limitations of such forward-looking statements. These documents contain and identify important factors that may cause actual results to differ materially from current expectations expressed or implied by our forward-looking statements. We undertake no obligation to update them to reflect subsequent events or circumstances except to the extent required by law. With that, I'd now like to hand the call over to Sean.

    Sean Saint CEO Thanks, Blake, and thanks, everyone, for joining. Q3 is usually a somewhat boring quarter in diabetes, with summer vacations and a lull of news after ADA. Today, we're going to do our best to spice it up a little bit with some great updates. So let's dive in. In September, we received FDA clearance for Mint, our transformative patch pump, which we expect to fully commercialize in the U.S. in Q1 of 2027. I feel this will ultimately prove to be the largest milestone achieved by the company to this point, and what an incredible effort it has been from the team to get that product designed, developed, and cleared by the FDA in a matter of about three years, which we believe is the fastest-ever timeline from concept to clearance for an automated insulin delivery, or AID, patch pump. We believe that Mint will be a game changer for people with diabetes. Starting in Q1 of next year, the only fully adaptive and most advanced insulin dosing algorithm in the U.S.

    Frequently Asked Questions About BBNX

    When is Beta Bionics, Inc. Common Stock's next earnings date?

    Beta Bionics, Inc. Common Stock's next earnings report is expected for Feb 15, 2027.

    Did BBNX beat earnings estimates last quarter?

    Yes. Beta Bionics, Inc. Common Stock reported EPS of -$0.52 for the quarter ended Sep 30, 2026, above the -$0.53 estimate, a 1.89% surprise.

    What EPS do analysts expect from BBNX next quarter?

    The consensus EPS estimate for Beta Bionics, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.51 from 16 analysts, with estimates from -$0.62 to -$0.45.

    How often does BBNX beat earnings estimates?

    Beta Bionics, Inc. Common Stock beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of -10.80%.